Clinical trial
Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
NCT02289144 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
- Lead sponsor
- University of Texas Southwestern Medical Center
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- June 30, 2015
- Completion date
- January 31, 2019
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced anaplastic, undifferentiated thyroid cancer, metastatic anaplastic thyroid cancer